The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 355:1278-1280 September 21, 2006 Number 12
NextNext

Stimulatory Autoantibodies to the PDGF Receptor in Scleroderma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Tan, F. K.
-Related Article
by Svegliati Baroni, S.
-PubMed Citation
To the Editor: In the study reported by Baroni et al. (June 22 issue),1 stimulatory antibodies to the platelet-derived growth factor (PDGF) receptor (PDGFR) were found in patients with scleroderma, and these autoantibodies appeared to play a role in the pathogenesis of the disease. The authors report that the stimulatory activity of the antibodies was higher in patients with early, limited scleroderma than in those with late disease. Pulmonary arterial hypertension (PAH), a life-threatening complication of scleroderma, is found in more than 15% of patients with this disease.2 PDGF involvement in the progression of PAH, presumably by increasing the proliferation . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.